Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) — Stella

Home/Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Lung Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

South Korea

SMC, Seoul, Kangnamgu

Samsung medical center, Seoul

Key details

Phase

Safety & dosing

Sponsor

Samsung Medical Center

Enrollment target

~43 participants

Started

July 2022

Primary completion

November 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

30 Years – 75 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.